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[Cyt6]AVP-(3-9). an intermediate in the metabolism of AVP-( 1-9) in vitro, was used to investigate the mech- 
anism of formation of centrally active AVP metabolites. Exposure of [Cyt6]AVP-(3-9) to rat brain mem- 
branes resulted in formation of [CytqAVP-(~-9), -(5-9). [pGlu4,CytqAVP-(~9) and AVP-(3-5) which were 
isolated and chemically identified. Products derived from cleavage of the C-terminus of the substrate were 
absent. Time-course experiments further indicated that the conversion process is predominantly mediby an 
aminopepttdase-like mechanism. The conversion of [CytqAVP-(3-9) by membranes from hippocampus, 
amygdala and septum was quantitatively and qualitatively similar. The results point to a major role of 
aminopeptidase activity m the metabohc conversion of AVP and the formation of centraliy active AVP 
metabolites. 
Vfisopressin Neuropeptide 
1. INTRODUCTION 
The proteolytic conversion of the neuropeptide 
[Arg’lvasopressin [AVP-( l-9); AVP] by brain 
synaptic membranes in vitro, like that of oxytocin 
and vasotocin, follows an aminopeptidase-like 
pathway [l-3]. C-terminal fragments, including 
[Cyt6]AVP-(2-9), (3-9), -(S-9) and [pGlu4,Cyt6] 
AVP-(4-9), have been identified as metabolities 
[1,3,4]. This conversion is of biological relevance 
since C-terminal fragments have central activities 
and are far more potent than AVP in their be- 
havioral activities [4,5]. The presence of such AVP 
metabolites in the brain and the existence of bind- 
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Peptidase Peptide metabolism 
ing sites for [~GIu~,~~ S-C~6]AVP-(4-9), which are 
different from [3H]AVP binding sites, have been 
demonstrated [6,7]. These findings suggest hat C- 
terminal AVP metabolites are a class of en- 
dogenous neuropeptides with distinct biological 
properties. 
The cyclization of the Gin4 residue to form 
[pGlu4,Cyt6]AVP-(4-9) is a significant event in the 
pathway of AVP conversion [ 1,4]. This modifica- 
tion protects the peptide against further aminopep- 
tidase conversion. Since the potency of behavioral 
activities of AVP metabolites resides in fpGlu4, 
C~6]-AVP-(4-9), [Cyt6JAVP-(5-9) and their 
des-Gly-NH2 derivatives, but not in [Cyt6]AVP- 
(3-9) [S], the enzymatic formation of the potent 
peptides and Gln cyclization were investigated in 
more detail by using [Cyt6]AVP-(3-9) as substrate. 
This paper reports the formation and identifica- 
tion of peptides derived from [Cyt6]AVP-(3-9) by 
in vitro processing by brain membranes. 
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2. MATERIALS AND METHODS 
2.1. Peptides 
The AVP fragments [Cyt6]AVP-(3-9), -(5-9), 
-(5-8), [pGlu4,Cyt6]AVP-(4-9) and -(4-B) were 
synthesized by Drs J.W. Van Nispen and H.M. 
Greven, Organon Internation~ BV, Oss, The 
Netherlands [8,9]. 
2.2. Incubations 
[Cyt6]AVP-(3-9) was incubated at 50 /IM with 
brain membranes in 40 mM sodium phosphate 
buffer, pH 7.0, at 37°C for various periods of 
time. Different protein concentrations were used 
as indicated in the legends to the figures. Incuba- 
tions were stopped by addition of HCl to 0.5 M 
(final concentration) and boiling for 10 min. 
Samples were centrifuged to remove membranes 
and subjected to HPLC by direct injection (sample 
volume s 1 ml) or freeze-drying and reconstitu- 
tion in 50 mM HOAc. 
2.3. High-pressure liquid c~romutogr~p~y 
AVP fragments were separated by paired-ion 
reverse-phase HPLC on a pBondapak Cl 8 column 
(Waters Associates, Millford, USA). The aqueous 
solvent (A) was 0.2410 (v/v) heptanesulfonic acid 
(PICB7 Reagent, Waters Associates); the organic 
solvent (B) was 0.1% (v/v) heptanesulfonic acid in 
methanol/Hz0 (5050). The concave gradient 
(curve 7 on Waters’ model 660 programmer) ran 
from 0 to 70% B in 30 min at a flow rate of 2.0 
mllmin. UV detection at 210 nm was used. 
2.4. Amino acid analyses 
The amino acid composition of samples was 
determined by HPLC of o-phthaldialdehyde 
derivatives of amino acids according to [IO]. Pep- 
tides were oxidized by performic acid treatment 
and hydrolyzed in 6 M HCI at 110°C for 18 h 
[l,lOl. 
3. RESULTS 
Development of a reverse-phase HPLC system 
based on ion pairing of peptides with heptane 
sulfonic acid enabled one to resolve various 
hydrophilic AVP fragments, which had little or no 
retention in an ammonium acetate/methanol 
HPLC solvent system [1,2]. Employing the paired- 
ion HPLC system several products of 
[Cyt6JAVP-(3-9), which were generated uring in- 
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Fig.1. Products of [Cyt6]AVP-(3-9) separated by paired-iron reverse-phase HPLC. [Cyt6JAVP-(3-9) (5 x lo-’ M) was 
incubated with brain membranes (2.5 mg protein/ml) in 5 ml of 40 mM sodium phosphate buffer, pH 7.0, at 37°C 
for 4 h. The total sample was subjected to HPLC as described in section 2. The fractions coded I-VI (in black) were 
purified in a second HPLC step and analyzed (see table I). The identity of products is given below the fractions. Compo- 
nent X is derived from the membrane preparation; components Y are contaminants of the mobile phase. The elution 
position of synthetic reference peptides is marked by arrows shown at the top. 
165 
Volume 197, number I,2 FEBS LETTERS 
TabIe 1 
Amino acid compositiona of peptides purified from digests of 
[Cyt6]AVP-(3-9) 
Amino acidb 1’ II III IV v VI 
Cys-acid - - 2.12 1.96 2.08 2.06 
AW - 0.98 1.03 0.94 1.03 0.99 
Ser - - - - - 
Glu - 1.01 1.00 0.04 0.96 0.98 
His - - _ - - - 
Arg - - 1.05 I.00 1.00 1.00 
GI y - - 0.83 0.91 O.% 0,87 
Thr - - _ - 
Ala - - - - 
Tyr - - - - 
Met - - - - 
Val - - - 
Phe 1.00 1.00 0.02 0.03 - 0.85 
IIe - - - 
Leu - - - 
LYS - - - 
AVP peptide Phe (3-5) [pGlu4,Cyt6]- [Cyt$- [Cyt’]- [Cyt6]- 
(4-9) (S-9) (4-9) (3-9) 
a Molar ratios of residues are given 
’ Pro is not detected by the amino acid anafysis system; Trp is 
destroyed upon performic acid oxydation and hydrolysis; -, 
below detection 
’ The sample numbers correspond to the fractions indicated in 
fig.1 
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cubation with brain membranes, were detected 
(fig.1). Each product was purified by rechro- 
matography in the same HPLC solvent system 
with a slightly modified gradient and chemically 
analyzed. Based on amino acid composition and 
N-terminal residues [pG~~4,C~~]AVP-~4-9~~ 
[Cyt6]AVP-(4-91, -(S-9), H-Phe-Gln-Asp-OH 
[AVP-(3-5)] and free Phe were identified as pro- 
ducts (table 1). 
In time-course experiments the peptide 
[C~6]AVP-(4-9) appeared initially as the predomi- 
nant product with lower amounts of the cyclized 
form [pGlu4,Cyt6]-AVP-(4-9) (fig.2). After pro- 
longed incubation [pGlu4, Cyt6]AVP was the main 
metabolite (fig.1). The amounts of [Cyt6]AVP- 
(5-9) always remained low, while the amount of H- 
Phe-Glu-Am-OH was bdow detection in the time- 
course experiment. 
Comparison of the conversion of [Cyt6]AVP- 
(3-9) by membranes (1 mg protein/ml) from the 
hippocampus, amygdala and septum showed no 
significant difference in the disappearance rate of 
the peptide; after 60 min of incubation the disap- 
pearance of [Cyt6]AVP-(3-9) was 71% for hip- 
pocampus, 74% for amygdafa and 70% for sep- 
tum, No differences were observed in the quahty 
of products nor in the time course of product 
accumulation. 
4. DISCUSSION 
In this paper the formation of AVP metabolites 
was investigated using ]Cyt6]AVP-(3-9), an in- 
termediate of AVP conversion, as substrate. The 
results show that the NHz-terminal Phe is rapidly 
released from this peptide to generate the 4-9 se- 
quence. This observation provides evidence for the 
interpretation of previous rest&s that consecutive 
aminopeptidase-like cleavages occur during con- 
version of AVP-(l-9) [l]. The presence of [Cyt6]- 
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Fig.2. Time-course of conversion of lCyt6]AVP-(3-9) and formation of products. [Cyt6)AVP-(3-9) (5 x lo-’ M) was 
incubated with 1 mg protein/ml of brain membranes a  in section 2. The composition of samples obtained at various 
time intervals was analyzed by HPLC. 
AVP-(5-9) in digests indicates that the aminopep- 
tidase activity proceeds beyond residue 4. 
Two forms of the 4-9 sequence were identified: 
[Cyt6]AVP-(4-9) and the N-terminal cyclized form 
[pGlu4,Cyt6]AVP-(4-9). The ratio of 4-9 peptides 
with free and cyclized N-terminus differed between 
individual experiments indicating that pGlu forma- 
tion is a spontaneous process not catalyzed by en- 
zymes. In particular under acidic conditions a free 
N-terminal Gln is known to cyclize readily into the 
pGlu form [9]. The time-dependent accumulation 
of [pGlu4,Cyt6]AVP-(4-9) observed here and in 
previous experiments [4] indicates that cyclization 
occurs during incubation rather than during ter- 
mination of enzyme reaction or preparation of 
samples for HPLC. In vitro pClu4 formation is an 
important structural modification which protects 
[pGlu4,Cyt6]AVP-(4-9) from further aminopep- 
tidase degradation. The finding that [Cyt6]AVP- 
(5-9) and -(5-8) are active in behavioral test situa- 
tions and differ only in potency from [pGlu4,Cyt6]- 
AVP-(4-9) and -(4-8) [7] indicates that the pGlu4 
is not prerequisite for biological activity. The 
presence of this residue in endogenous forms of 
AVP metabolites [5] remains to be investigated. 
The identi~cation of the peptide H-Phe-Gln- 
AsnJOH points to cleavage of the Asn’-Cys’ bond 
in [Cyt6]AVP-(3-9), probably by an endopep- 
tidase. The complementary peptide [Cyt6]AVP- 
(6-9) has not been identified in these experiments, 
however. The cleavage is of minor importance 
since the tripeptide appeared only in very small 
quantities. This cleavage has not been recognized 
before in experiments using AVP-(1-9) as 
substrate. It may be possible that this cleavage only 
occurs in linearized AVP metabolites like [Cyt6] 
AVP-(2-9), -(3-9) or smaller, but not in 
AVP-(l-9) which has a rigid ring structure. 
The absence of des-Gly-NH2 fragments in the 
present study is noteworthy. [pGlu4,Cyt6]AVP- 
(4-8) and [Q@]AVP-(5-8) have significant 
behavioral activities [4,5] and Gly-NH2 is released 
during conversion of AVP-(l-9) at a rate which is 
10% of the aminopeptidase mediated release of 
Tyr’ [1,3]. Apparently, the activity of the C- 
terminal cleaving enzyme on [Cy?]AVP-(3-9) re- 
mains far behind the aminopeptidase activity and 
does not play a significant role in vitro in modify- 
ing the C-terminal AVP metabolites. In contrast to 
membranes of rat and chicken brain, high C- 
terminal cleaving activity is present in membranes 
of frog brain [2,12]. 
Different behavioral effects can be elicited by 
microinjection of AVP-(1-9) in limbic brain areas 
like hippo~ampus, amygdala and septum [l 11. 
These differences may be due to differences in for- 
mation of behaviorally active fragments. 
However, the quantitative and qualitative similari- 
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ty of conversion of [Cyt6]AVP-(3-9) by mem- 
branes from these areas indicates that such dif- 
ferences cannot be detected in vitro using isolated 
fractions or that other factors than metabolism 
cause the differences in behavioral response. 
In conclusion, the formation of active AVP 
metabolites involves [Cyt6]-AVP-(3-9) as an in- 
termediate, and is based on the action of an 
aminopeptidase activity. The aminopeptidase ac- 
tion may be blocked by spontaneous pGlu 
formation. 
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